TruPlan vs QFR

QFR (Medis QFR) emphasizes a user-friendly interface and a simplified workflow, reducing steps from seven to three in its latest version, aiming for analysis in approximately 30 seconds. It integrates seamlessly with cath lab systems for real-time or retrospective analysis, and its AI-enabled end-diastolic frame selection minimizes user variability. TruPlan also offers intuitive controls and a simplified workflow for LAAC, but QFR's focus on eliminating invasive wires and hyperemic agents, coupled with its streamlined analysis steps, gives it an edge in immediate procedural efficiency and ease of use.

Both tools are FDA-cleared and offer significant clinical value. TruPlan enhances pre-procedural planning and post-procedural follow-up for LAAC, leading to improved procedural efficiency and outcomes. However, QFR has extensive clinical evidence, including large-scale randomized trials demonstrating superior clinical outcomes compared to angiography-guided strategies, with a 35% reduction in one-year rates of heart attack and a lesser chance of needing additional PCI. Its strong correlation with FFR and inclusion in ESC guidelines for evaluating coronary stenoses highlight its robust clinical validation and impact on patient care.

While TruPlan provides some transparency by mentioning its resale through Boston Scientific and a subscription model for its broader platform, QFR explicitly highlights its cost-effectiveness. QFR eliminates the need for expensive consumables like pressure wires and hyperemic agents (adenosine), which are required for traditional FFR measurements, thereby simplifying the procedure and reducing overall costs. Some sources suggest a one-time cost per QFR result, further emphasizing its value proposition.

TruPlan explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for enterprise adoption. Its parent company, Circle Cardiovascular Imaging, positions its cvi42 platform for enterprise integration, offering a unified architecture for security, simplified integrations with PACS/VNA, EMR, DICOM, and HL7, and predictable performance. The partnership with Boston Scientific for resale further enhances its enterprise reach and support infrastructure.

Both tools are innovative in their respective domains. TruPlan's comprehensive suite of AI-enabled simulations (TEE, ICE, Fluoroscopic) for pre-procedural planning of complex LAAC procedures represents a significant advancement in procedural guidance. However, QFR's core innovation lies in its ability to non-invasively derive functional significance (equivalent to FFR) from standard angiographic images using AI and computational fluid dynamics, eliminating the need for invasive wires and drugs. This fundamental shift in assessing coronary physiology has a broader impact on diagnostic workflows, patient experience, and cost-effectiveness.

TruPlan benefits from a robust support structure, leveraging both Circle Cardiovascular Imaging's highly-rated global customer support, which boasts industry-leading Net Promoter Scores and Customer Satisfaction scores, and the extensive field support provided by Boston Scientific's clinical and sales representatives for WATCHMAN procedures. Circle CVI also provides comprehensive documentation and tutorials. While Medis QFR (Tool B) also offers documentation and has partnerships, the explicit high customer satisfaction metrics and the dual-layer support network for TruPlan indicate a more established and proven support system.